Cytokines and autoantibodies to cytokines

STEM CELLS

Volumn 13, Issue 3, 1995, Pages 206-222

  Bendtzen, Klaus ^a   Hansen, Morten B ^a   Ross, Christian ^a   Poulsen, Lars K ^a   Svenson, Morten ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Autoantibody; IFN ; IL 10; IL 1 ; IL 6; Interferons; Interleukins; LIF; Natural regulation; Review

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 14; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; INTERLEUKIN RECEPTOR; LEUKEMIA INHIBITORY FACTOR; LYMPHOTOXIN; MIGRATION INHIBITION FACTOR; ONCOSTATIN M; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AUTOIMMUNITY; B LYMPHOCYTE; ETIOLOGY; GENE LOCATION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; REVIEW; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY AFFINITY; AUTOANTIBODIES; CYTOKINES; FEMALE; HUMAN; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MALE; SUPPORT, NON-U.S. GOV'T;

EID: 0029057205     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.5530130303     Document Type: Article

References (79)

1. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic diseases and endocrine diseases
2. Interleukin 1 and interleukin 1 antagonism
3. Cytokine network and the vessel wall: insights into septic shock pathogenesis
4. The interleukin 1 system: receptors, ligands and signals
5. Immunoinflammatory mediators (cytokines) in trauma: natural regulation and intervention with systemic complications
6. Interferon‐γ: a key immunoregulatory lymphokine
7. Cytokines and cancer cachexia
8. Interleukin 1 receptor antagonist
9. Interleukin 2: a review of its pharmacological properties and therapeutic use in patients with cancer
10. Interleukin 6 in biology and medicine
11. Interleukin 8 and related chemotactic cytokines–CXC and CC chemokines
12. Interleukin 12
13. Lymphocyte responses and cytokines
14. Cytokine signal transduction
15. Endothelial cell production of nitrogen oxides in response to interferon γ in combination with tumor necrosis factor, interleukin 1, or endotoxin
16. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half‐life
17. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity
18. Clinical significance of cytokines: natural and therapeutic regulation
19. Plasma level of IL‐1β in disseminated intravascular coagulation
20. Tumor necrosis factor: alpha and beta subtypes appear in circulation during onset of sepsis‐induced lung injury
21. Tumor necrosis factor mediates disseminated intravascular inflammation (DII) in the genesis of multiple organ edema
22. Essential role for interferon‐γ and interleukin 6 in autoimmune insulin‐dependent diabetes in NOD/Wehi mice
23. Cytokines in intestinal inflammation: pathophysiological and clinical considerations
24. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue
25. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β
26. Determination of endogenous cytokines in chronic wounds
27. Interleukin 6 activity in wounds
28. Cytokines and smooth muscle cells in atherosclerosis
29. Atherogenesis and inflammation
30. Biological properties of interleukin 10
31. Interleukin 10
32. Interleukin 10 (IL‐10) and viral IL‐10 strongly reduce antigen‐specific human T cell proliferation by diminishing the antigen‐presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression
33. Interleukin 10 (IL‐10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL‐10 produced by monocytes
34. Interleukin 10 and transforming growth factor β cooperate to induce anti‐CD40‐activated naive human B cells to secrete immunoglobulin A
35. Local expression of antiinflammatory cytokines in cancer
36. Interleukin 10 production by human carcinoma cell lines and its relationship to interleukin 6 expression
37. Differential expression of viral and human interleukin 10 (IL‐10) by primary B cell tumors and B cell lines
38. Production of interleukin 10 by human bronchogenic carcinoma
39. Interleukin 10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages
40. Cytokine cross‐talk between phagocytic cells and lymphocytes: relevance for differentiation/activation of phagocytic cells and regulation of adaptive immunity
41. Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein‐Barr virus protein BCRF1
42. Characteristics of autoantibodies to human interferon in a patient with varicella‐zoster disease
43. Natural antibodies to interferon‐alpha and interferon‐beta are a common feature of inbred mouse strains
44. IgG autoantibodies against interleukin 1α in sera of normal individuals
45. Interferon‐α antibodies in autoimmune diseases
46. Interleukin 1‐inhibitory IgG in sera from some patients with rheumatoid arthritis
47. Autoantibodies to cytokines—friends or foes?
48. Distribution and characterization of autoantibodies to interleukin 1α in normal human sera
49. Demonstration of neutralizing autoantibodies against IL‐1α in sera from patients with rheumatoid arthritis
50. Anti‐interleukin 6 antibodies in normal human serum
51. Human anti‐interleukin 1α antibodies
52. Identification of high‐affinity anti‐IL‐1α autoantibodies in normal human serum as an interfering substance in a sensitive enzyme‐linked immunosorbent assay for IL‐1α
53. Anti‐interleukin 1α autoantibodies in humans: characterization, isotype distribution, and receptor‐binding inhibition—higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia)
54. Anti‐IL‐1α autoantibodies in patients with rheumatic diseases and in healthy subjects
55. Anti‐interleukin 1α autoantibodies in hemodialysis patients
56. Cytokine‐induced histamine release from basophils of AIDS patients: interaction between cytokines and specific IgE antibodies
57. Characterization and detection of naturally occurring antibodies against IL‐1α and IL‐1β in normal human plasma
58. Anti‐interleukin 6 autoantibodies in rheumatic diseases: increased frequency in the sera of patients with systemic sclerosis
59. Effects of human anti‐IL‐1α autoantibodies on receptor binding and biological activities of IL‐1
60. High levels of “complexed” interleukin 6 in human blood
61. High‐affinity IgG autoantibodies to IL‐6 in sera of normal individuals are competitive inhibitors of IL‐6 in vitro
62. IL‐6‐anti‐IL‐6 autoantibody complexes with IL‐6 activity in sera from some patients with systemic sclerosis
63. Sex‐ and age‐dependency of IgG auto‐antibodies against IL‐1α in healthy humans
64. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin
65. Characterization of anti‐IL‐1α autoantibodies in the sera from healthy humans
66. Naturally‐occurring autoantibodies to IL‐1α, IL‐6, IL‐10 and IFNα
67. Specific autoantibodies directed against interferon‐α in pharmaceutically prepared human immunoglobulin preparations
68. Auto‐antibodies to tumour necrosis factor α in healthy humans and patients with inflammatory diseases and gram‐negative bacterial infections
69. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN‐α2b and human IFN‐γ in healthy blood donors
70. Neutrophil attractant protein‐1‐immunoglobulin G immune complexes and free anti‐NAP‐1 antibody in normal human serum
71. The role of human autoantibodies against γ‐interferon
72. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease
73. The detection and biological activity of human antibodies to IL‐2 in normal donors
74. Neutrophil attractant protein‐1 and monocyte chemoattractant protein‐1 in human serum: effects of intravenous lipopolysaccharide on free attractants, specific IgG autoantibodies and immune complexes
75. Serum‐induced suppression of interferon (IFN) activity: lack of evidence for the presence of specific autoantibodies to IFN‐α in normal human sera
76. Monoclonal antibodies to murine IL‐1α: production, characterization, and inhibition of membrane‐associated IL‐1 activity
77. The costimulatory function of antigen‐presenting cells
78. Manipulating the immune system with immune globulin
79. Kawasaki disease and IVIG treatment